Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Bijal D. Shah,Olalekan O. Oluwole,Maria R. Baer,Michael R. Bishop,Houston Holmes,Gary J. Schiller,William B. Donnellan,Kristen Marie Carr-ODwyer,Armen Mardiros,John M. Rossi,Tong Shen,Allen Xue,Rajul K. Jain,Remus Vezan,William G. Wierda

Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

2018

Bijal D. Shah
Olalekan O. Oluwole
Maria R. Baer
Michael R. Bishop
Houston Holmes
Gary J. Schiller
William B. Donnellan
Kristen Marie Carr-ODwyer
Armen Mardiros
John M. Rossi
Tong Shen
Allen Xue
Rajul K. Jain
Remus Vezan
William G. Wierda

7006Background: KTE-C19 showed promising efficacy (71% complete response [CR] or CR with incomplete hematologic recovery [CRi]) and manageable safety for pts with R/R ALL in Phase 1 of ZUMA-3 (Shah...

Keywords:

Chimeric antigen receptor
Refractory
Pathology
CAR T-cell therapy
Lymphoblastic Leukemia
Cancer research
Blinatumomab
Medicine
CD19
anti cd19
complete response
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations